Adlabs, film processing major reported a sharp drop in performance for 2QFY02. While sales dropped by 24% sequentially, operating margins dipped to a 21.5% compared to 35.8% in 1QFY02. Finally, PBT recorded a drop of around 52%.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
The sharp drop in peformance has been on two counts. While film processing business dipped due to absence of any mega movies during the quarter, the capacity utilisation in its IMAX venture is taking a toll. The drop in operating margins thus could be justified by the fact that the business model of the company is tilted towards high fixed cost. For example, while staff costs recorded a jump of more than 37% due to commencing of IMAX theatre. However, revenues from IMAX failed to match up with increase in fixed costs.
Adlabs Revenue Mix
At the current market price of Rs 50, the stock is quoting at 14x its 2QFY02 annualised earnings. The multiplex theatres which have become operational are expecte to contribute considerable revenues in the currrent quarter. Under the new government policy on multiplex theatres the company enjoys exemption from entertainment tax. Though the company seems to be cautious in its ad-spends and other marketing expenses, fixed costs are expected to be higher this quarter. Though the film processing business has recorded a sharp drop, it remains a cash cow for the company. However, the fortunes of the company are intrinsicly linked to the utilisation rates of the Imax and multiplex theaters. The company has a huge fixed cost bill for running these ventures and in case utilisation rates don't pick up, there could be considerable further drop in operating margins. Further, considering that these projects will take atleast 3 years to breakeven, RoCE would continue to remain under strain.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407